Champions Oncology Analyst Price Targets - Benzinga

Champions Oncology Inc

CSBRNASDAQ

Trade with Public

Trade with Public

$4.84

-0.14-2.81%

Dern. MÀJ: Oct 7, 7:56 AM

$5.00

0.020.4%

Aperçu Actualités Prévisions de résultats ÉvénementsObjectifs de coursDonnées financières Sentiment Actionnariat Comparer Options Rapport sur les stocks

Champions Oncology Analyst Price Targets - Benzinga

Champions Oncology Analyst Price Targets

Wall Street analyst price targets and consensus rating for Champions Oncology (CSBR).

Price Target Range — 3 Quarters

Analyst Consensus — 1 Analysts

1Buy

Consensus RatingBuy# Analysts1Avg. Consensus PT$12Upside to Avg. PT+140.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Mar 12, 2025	Craig-Hallum	Matt Hewitt	PT Raise	Buy	$8→$12
Dec 12, 2024	Craig-Hallum	Matt Hewitt	PT Raise	Buy	$6→$8
Sep 12, 2024	Craig-Hallum	Matt Hewitt	Upgrade	Hold→Buy	$6
Mar 13, 2024	Craig-Hallum	Matt Hewitt	Downgrade	Buy→Hold	—

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Craig-Hallum Maintains Buy on Champions Oncology, Raises Price Target to $12

Craig-Hallum analyst Matt Hewitt maintains Champions Oncology (NASDAQ:CSBR) with a Buy and raises the price target from $8 to $12.

Benzinga Newsdesk

PRO
Craig-Hallum Maintains Buy on Champions Oncology, Raises Price Target to $8

Craig-Hallum analyst Matt Hewitt maintains Champions Oncology (NASDAQ:CSBR) with a Buy and raises the price target from $6 to $8.

Benzinga Newsdesk

PRO
Craig-Hallum Upgrades Champions Oncology to Buy, Maintains Price Target to $6

Craig-Hallum analyst Matt Hewitt upgrades Champions Oncology (NASDAQ:CSBR) from Hold to Buy and maintains the price target from $6 to $6.

Benzinga Newsdesk

PRO
Craig-Hallum Downgrades Champions Oncology to Hold

Craig-Hallum analyst Matt Hewitt downgrades Champions Oncology (NASDAQ:CSBR) from Buy to Hold.

Benzinga Newsdesk

PRO
Roth MKM Maintains Buy on Champions Oncology, Lowers Price Target to $7.5

Roth MKM analyst Scott Henry maintains Champions Oncology (NASDAQ:CSBR) with a Buy and lowers the price target from $9 to $7.5.

Benzinga Newsdesk

PRO
Roth Capital Maintains Buy on Champions Oncology, Raises Price Target to $16

Roth Capital maintains Champions Oncology (NASDAQ:CSBR) with a Buy and raises the price target from $13.5 to $16.

Benzinga Newsdesk